17:07 EDT Corbus Pharmaceuticals (CRBP) files $300M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals price target raised to $57 from $53 at Oppenheimer
- Corbus Pharmaceuticals: Advancing Best-in-Class Nectin-4 ADC and Emerging Obesity Franchise Support Buy Rating
- Corbus: Buy Rating Backed by CRB-701 Oncology Potential, Obesity Pipeline Catalysts, and Cash Runway Into 2028
- Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress
- Corbus Pharmaceuticals reports Q4 EPS ($1.25), consensus ($1.58)